利妥昔单抗治疗微小病变性肾病的疗效分析

Analysis of the Efficacy of Rituximab in Microlesional Nephropathy

目的 探讨利妥昔单抗治疗微小病变性肾病的疗效。方法 非随机选取2022年1月-2023年12月浙江省人民医院收治的60例微小病变性肾病患者,按治疗方法分为两组。对照组30例采用激素续贯疗法,观察组30例采用利妥昔单抗联合激素续贯疗法。对比两组治疗效果、生化指标、不良反应发生率以及复发率。结果 观察组治疗效果优于对照组,差异有统计学意义(P<0.05)。观察组生化指标水平优于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。观察组复发率为7.14%(2/28),低于对照组的34.78%(8/23),差异有统计学意义(χ^(2)=4.492,P=0.034)。结论 利妥昔单抗治疗微小病变性肾病,能提高治疗效果,改善临床症状,且安全性良好,降低复发率。

Objective To explore the efficacy of rituximab in microlesional nephropathy.Methods Sixty cases of mi-croscopic lesion nephropathy patients admitted to Zhejiang Provincial People′s Hospital from January 2022 to Decem-ber 2023 were non-randomly selected and divided into two groups according to treatment methods.Thirty cases in the control group were treated with hormone sequestration therapy,and thirty cases in the observation group were treated with rituximab combined with hormone sequestration therapy.Compared the treatment effect,biochemical indexes,in-cidence of adverse reactions and recurrence rate of the two groups.Results The therapeutic effect of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).The level of biochemical indexes of the observation group were better than those of the control group,and the differences were sta-tistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).The recurrence rate of the observation group was 7.14%(2/28),which was lower than 34.78%(8/23)in the control group,and the difference was statistically significant(χ^(2)=4.492,P=0.034).Conclu-sion Rituximab treatment for microscopic lesion nephropathy improves treatment efficacy and clinical symptoms with a favorable safety profile and reduced relapse rate.